Trial Profile
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Bizaxofusp (Primary) ; Bizaxofusp (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Medicenna Therapeutics
- 14 Feb 2024 According to a Medicenna Therapeutics media release, the company plans to seek to apply for Breakthrough Therapy Designation (BTD) for bizaxofusp based on compelling data from this trial presented at the SNO.
- 17 Nov 2023 Results presented in the Medicenna Therapeutics media release.
- 17 Nov 2023 According to a Medicenna Therapeutics media release, the company announced that a poster presentation and an oral summary highlighting longer term follow up results from the Phase 2b clinical trial of bizaxofusp), will be presented by Dr. Steven Brem, M.D. at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada.